Ferumoxytol-enhanced Magnetic Resonance Imaging

Summary

There are no current alternatives to diagnostic contrast-requiring imaging for patients with an eGFR \<30mL/min due to the association of gadolinium-based imaging modalities to nephrogenic systemic fibrosis and iodinated contrast-induced kidney injury. Ferumoxytol-enhanced imaging may offer an alternative approach.

Timeline

Start

2017-02-01

Primary completion

2023-11-01

Completion

2024-02-27

Publications

• Chin MS, Steigner M, Yin W, Kwong RY, Siedlecki AM. Intraluminal Assessment of Coronary Arteries With Ferumoxytol-Enhanced Magnetic Resonance Angiography. JACC Cardiovasc Imaging. 2018 Mar;11(3):505-508. doi: 10.1016/j.jcmg.2017.10.017. Epub 2017 Dec 13. No abstract available.

Drugs

Indications